Alcon and RxSight Announce Collaboration to Develop Adjustable IOLs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
The firm states: "Alcon (ALC) and RxSight (RXST) announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses, or PCIOLs. Under the collaboration, the companies will be innovating on their respective platforms - RxSight's post-operative light-adjustable technology and Alcon's PCIOL optical designs - and combining them to create a co-developed technology that enables surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL. As part of the agreement, RxSight will receive a $60 million upfront payment to begin development. RxSight could receive up to an additional $140 million in payments as development and regulatory milestones are met. Under the agreement, Alcon will lead global commercialization, while RxSight will be responsible for development and manufacturing and receive royalties on net sales."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALC
Wall Street analysts forecast ALC stock price to rise
13 Analyst Rating
7 Buy
5 Hold
1 Sell
Moderate Buy
Current: 66.870
Low
78.17
Averages
93.73
High
117.26
Current: 66.870
Low
78.17
Averages
93.73
High
117.26
About ALC
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alcon and Mexican Gold Finalize Arrangement Agreement
- Shareholder Approval: Alcon Silver Corp. received a 66.67% majority approval from shareholders and debenture holders at its annual meeting on July 3, 2026, validating the strategic arrangement with Mexican Gold and marking a significant step in corporate consolidation.
- Court Approval Application: Alcon plans to apply for a final court order on July 8, 2026, at the Supreme Court of British Columbia to approve the arrangement, which, if granted, will provide legal backing for the transaction and facilitate the merger process.
- Transaction Closing Timeline: If the final court order is approved, Alcon and Mexican Gold expect to close the transaction around July 15, 2026, laying the groundwork for resource integration and market expansion, thereby enhancing competitiveness in the mining sector.
- Strategic Development Outlook: The completion of this arrangement agreement not only aids in resource consolidation for Alcon and Mexican Gold but also propels both companies' mineral development efforts in the Americas, strengthening their market position in precious metals and copper projects.
See More
Alcon Partners with RxSight to Develop Adjustable Intraocular Lenses
- Collaboration Agreement: Alcon has entered a non-exclusive collaboration with RxSight, which will receive an upfront payment of $60 million to support the development of adjustable presbyopia-correcting intraocular lenses, with an additional $140 million contingent on achieving specific milestones, bringing the total potential deal value to $200 million.
- Technological Integration: This partnership aims to combine RxSight's post-operative light-adjustable technology with Alcon's optical designs for intraocular lenses, enabling more precise visual adjustments for cataract patients opting for these lenses, thereby enhancing surgical outcomes.
- Market Commercialization Strategy: Alcon will lead global commercialization while RxSight will handle development and manufacturing, with RxSight eligible for royalties on net sales, a division of responsibilities that is expected to accelerate product launch and expand market share.
- Stock Performance Overview: Alcon's stock has traded between $61.83 and $92.55 over the past year, closing at $68.33, indicating cautious optimism in the market regarding the collaboration's prospects; RxSight's stock has fluctuated between $4.48 and $13.36, closing at $5.60, reflecting market interest in its technology.
See More
Alcon and RxSight Collaborate on Adjustable Intraocular Lens Development
- Collaboration Agreement: Alcon and RxSight have signed a non-exclusive collaboration agreement to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), aiming to enhance visual outcomes after cataract surgery by leveraging both companies' strengths in ophthalmic technology.
- Financial Support: RxSight will receive a $60 million upfront payment to initiate development, with potential additional payments of up to $140 million as development and regulatory milestones are achieved, providing robust financial backing for its technological innovations.
- Market Leadership: Alcon will lead global commercialization while RxSight will handle development and manufacturing, receiving royalties on net sales; this division of responsibilities is expected to accelerate the market introduction of new products and further solidify both companies' leadership positions in the ophthalmic device market.
- Patient Benefits: This collaboration will not only provide patients with higher quality customized vision experiences but also promote the adoption of adjustable technologies, addressing the growing market demand and enhancing patients' quality of life.
See More
Alcon and RxSight Collaborate on Adjustable Intraocular Lens Development
- Collaborative Development: Alcon and RxSight have entered into a non-exclusive agreement to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), aiming to combine the best technologies from both companies to enhance visual outcomes post-cataract surgery.
- Funding and Milestones: RxSight will receive a $60 million upfront payment and could earn an additional $140 million upon achieving development and regulatory milestones, providing robust financial support for the technology's development and facilitating its market introduction.
- Market Leadership: Alcon will lead global commercialization while RxSight will handle development and manufacturing, receiving royalties on net sales; this division of responsibilities is expected to accelerate market penetration of the new product and enhance both companies' competitiveness in the ophthalmic market.
- Customized Patient Experience: The collaboration underscores the importance of adjustability, which is anticipated to provide more patients with personalized vision solutions, further driving innovation in ophthalmic surgery and improving patient satisfaction.
See More
Alcon Q1 2026 Earnings Call Insights Highlight Strong Market Gains
- Significant Sales Growth: Alcon reported Q1 sales of $2.7 billion, a 6% increase year-over-year, with surgical equipment sales reaching $253 million, up 23%, indicating strong momentum from the Unity product line that is expected to further enhance market share.
- Strong New Product Performance: The PanOptix Pro has driven nearly 2 percentage points of growth in the U.S. PC-IOL category, while Tryptyr has captured approximately 4 percentage points of market share just 8 months post-launch, demonstrating the company's ongoing competitiveness in the dry eye segment.
- Share Repurchase Program: The Board has approved a new $1.5 billion share repurchase program to be executed over the next three years, which is expected to be supported by an estimated $25 million reduction in tariff expenses earmarked for reinvestment, thereby enhancing shareholder value.
- Optimistic Future Outlook: The company continues to expect sales growth of 5% to 7% for 2026, with an aggregate eye care market growth assumption of 3% to 4%, while core diluted EPS is projected to grow between 10% and 13%, reflecting management's confidence in the market.
See More
Alcon (ALC) Q1 2026 Earnings Call Transcript
See More
Alcon and Mexican Gold Finalize Arrangement Agreement
- Shareholder Approval: Alcon Silver Corp. received a 66.67% majority approval from shareholders and debenture holders at its annual meeting on July 3, 2026, validating the strategic arrangement with Mexican Gold and marking a significant step in corporate consolidation.
- Court Approval Application: Alcon plans to apply for a final court order on July 8, 2026, at the Supreme Court of British Columbia to approve the arrangement, which, if granted, will provide legal backing for the transaction and facilitate the merger process.
- Transaction Closing Timeline: If the final court order is approved, Alcon and Mexican Gold expect to close the transaction around July 15, 2026, laying the groundwork for resource integration and market expansion, thereby enhancing competitiveness in the mining sector.
- Strategic Development Outlook: The completion of this arrangement agreement not only aids in resource consolidation for Alcon and Mexican Gold but also propels both companies' mineral development efforts in the Americas, strengthening their market position in precious metals and copper projects.
See More
Alcon Partners with RxSight to Develop Adjustable Intraocular Lenses
- Collaboration Agreement: Alcon has entered a non-exclusive collaboration with RxSight, which will receive an upfront payment of $60 million to support the development of adjustable presbyopia-correcting intraocular lenses, with an additional $140 million contingent on achieving specific milestones, bringing the total potential deal value to $200 million.
- Technological Integration: This partnership aims to combine RxSight's post-operative light-adjustable technology with Alcon's optical designs for intraocular lenses, enabling more precise visual adjustments for cataract patients opting for these lenses, thereby enhancing surgical outcomes.
- Market Commercialization Strategy: Alcon will lead global commercialization while RxSight will handle development and manufacturing, with RxSight eligible for royalties on net sales, a division of responsibilities that is expected to accelerate product launch and expand market share.
- Stock Performance Overview: Alcon's stock has traded between $61.83 and $92.55 over the past year, closing at $68.33, indicating cautious optimism in the market regarding the collaboration's prospects; RxSight's stock has fluctuated between $4.48 and $13.36, closing at $5.60, reflecting market interest in its technology.
See More
Alcon and RxSight Collaborate on Adjustable Intraocular Lens Development
- Collaboration Agreement: Alcon and RxSight have signed a non-exclusive collaboration agreement to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), aiming to enhance visual outcomes after cataract surgery by leveraging both companies' strengths in ophthalmic technology.
- Financial Support: RxSight will receive a $60 million upfront payment to initiate development, with potential additional payments of up to $140 million as development and regulatory milestones are achieved, providing robust financial backing for its technological innovations.
- Market Leadership: Alcon will lead global commercialization while RxSight will handle development and manufacturing, receiving royalties on net sales; this division of responsibilities is expected to accelerate the market introduction of new products and further solidify both companies' leadership positions in the ophthalmic device market.
- Patient Benefits: This collaboration will not only provide patients with higher quality customized vision experiences but also promote the adoption of adjustable technologies, addressing the growing market demand and enhancing patients' quality of life.
See More
Alcon and RxSight Collaborate on Adjustable Intraocular Lens Development
- Collaborative Development: Alcon and RxSight have entered into a non-exclusive agreement to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), aiming to combine the best technologies from both companies to enhance visual outcomes post-cataract surgery.
- Funding and Milestones: RxSight will receive a $60 million upfront payment and could earn an additional $140 million upon achieving development and regulatory milestones, providing robust financial support for the technology's development and facilitating its market introduction.
- Market Leadership: Alcon will lead global commercialization while RxSight will handle development and manufacturing, receiving royalties on net sales; this division of responsibilities is expected to accelerate market penetration of the new product and enhance both companies' competitiveness in the ophthalmic market.
- Customized Patient Experience: The collaboration underscores the importance of adjustability, which is anticipated to provide more patients with personalized vision solutions, further driving innovation in ophthalmic surgery and improving patient satisfaction.
See More
Alcon Q1 2026 Earnings Call Insights Highlight Strong Market Gains
- Significant Sales Growth: Alcon reported Q1 sales of $2.7 billion, a 6% increase year-over-year, with surgical equipment sales reaching $253 million, up 23%, indicating strong momentum from the Unity product line that is expected to further enhance market share.
- Strong New Product Performance: The PanOptix Pro has driven nearly 2 percentage points of growth in the U.S. PC-IOL category, while Tryptyr has captured approximately 4 percentage points of market share just 8 months post-launch, demonstrating the company's ongoing competitiveness in the dry eye segment.
- Share Repurchase Program: The Board has approved a new $1.5 billion share repurchase program to be executed over the next three years, which is expected to be supported by an estimated $25 million reduction in tariff expenses earmarked for reinvestment, thereby enhancing shareholder value.
- Optimistic Future Outlook: The company continues to expect sales growth of 5% to 7% for 2026, with an aggregate eye care market growth assumption of 3% to 4%, while core diluted EPS is projected to grow between 10% and 13%, reflecting management's confidence in the market.
See More
Alcon (ALC) Q1 2026 Earnings Call Transcript
See More
